Non invasive Cell Based Liquid Biopsy Platform for Bladder Cancer

Project Information

OneRNA4Bladder

Grant agreement ID: 783654

DOI 10.3030/783654

Project terminated on 19 March 2020

EC signature date 24 November 2017

Start date 1 December 2017

End date 30 November 2020

Funded under

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Total cost € 3 713 994,25

EU contribution € 3 713 994,25

Coordinated by

GENOMIC EXPRESSION APS
Denmark

Objective

OneRNA4Bladder aims to save lives and reduce cost of care for bladder cancer treatment – the most expensive type of cancer to treat due to expensive diagnostic procedures and ineffective drugs leading to a recurrence rate of 70%. Implementing the OneRNA4Bladder system for bladder cancer recurrence detection could cut the cost of managing bladder cancer in half, resulting in savings of more than €800 million/year in Europe

The key project technology is a patented Urine Cancer Cell Filtration Device (UCCFD) that enables the selection of tumor cells from a simple urine sample. The UCCFD was developed and validated in a small prospective clinical study by the Danish Cancer Society and in-licensed by Genomic Expression Aps (GEx). In OneRNA4Bladder, GEx aims at the clinical validation of the UCCFD – in combination with DNA biomarkers – for the detection of bladder cancer recurrence. Furthermore, the UCCFD can – in combination with GEx’s proprietary OneRNA™ platform, which links RNA's to drugs that can provide a more effective treatment – be applied as a liquid biopsy platform to monitor the disease response to treatment without invasive biopsies or cystoscopies. In OneRNA4Bladder, we will also clinically validate the UCCFD technology together with OneRNA™ as a liquid biopsy platform.

OneRNA4Bladder is an opportunity for GEx to enter the world-wide bladder cancer diagnostic market. The accomplishment of the project objectives will represent a significant business opportunity for the SME, with expected sales of over €165 million within 5 years of launch.

Fields of science

• medical and health sciences › clinical medicine › oncology › bladder cancer
• medical and health sciences › medical biotechnology › genetic engineering › gene therapy
• natural sciences › biological sciences › genetics › DNA
• medical and health sciences › basic medicine › pharmacology and pharmacy › pharmaceutical drugs › vaccines
• natural sciences › biological sciences › genetics › RNA

Keywords

• bladder cancer
• recurrence
• urine cancer cell filtration device
• DNA
• RNA
• non-invasive
• cost
• reduction

Programme(s)

• H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme
• H2020-EU.3.1.3. - Treating and managing disease

Topic(s)

• SMEInst-05-2016-2017 - Supporting innovative SMEs in the healthcare biotechnology sector

Call for proposal

H2020-SMEInst-2016-2017

See other projects for this call

Sub call

H2020-SMEINST-2-2016-2017

Funding Scheme

SME-2 - SME instrument phase 2

Coordinator

GENOMIC EXPRESSION APS

• Net EU contribution: € 3 713 994,25
• Address: BORGSKRIVERVEJ 3 2 TH ; 2400 Kobenhavn Nv ; Denmark
• SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes:
  Region
  Danmark › Hovedstaden › Byen København
• Region: Danmark › Hovedstaden › Byen København
• Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
• Total cost: € 3 713 994,25